Assembly Bio aspires to deliver finite and curative therapies for chronic hepatitis B virus (HBV) infection, one of the world’s most prevalent and devastating infectious diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
- Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
Feb 26, 2021 at 1:40 PM EST
Feb 25, 2021 at 5:00 PM EST
Nov 17, 2020 at 2:55 PM EST